Cargando…

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy

Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pei, Yuan, Yadi, Cui, Bopei, Huo, Yaqian, Bian, Lianlian, Chen, Lei, Liu, Siyuan, Wang, Chenfei, Xu, Yingzhi, Tedcastle, Alison, Gao, Fan, Mao, Qunying, Martin, Javier, Liang, Zhenglun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143144/
https://www.ncbi.nlm.nih.gov/pubmed/33919184
http://dx.doi.org/10.3390/v13050720
_version_ 1783696698496778240
author Liu, Pei
Yuan, Yadi
Cui, Bopei
Huo, Yaqian
Bian, Lianlian
Chen, Lei
Liu, Siyuan
Wang, Chenfei
Xu, Yingzhi
Tedcastle, Alison
Gao, Fan
Mao, Qunying
Martin, Javier
Liang, Zhenglun
author_facet Liu, Pei
Yuan, Yadi
Cui, Bopei
Huo, Yaqian
Bian, Lianlian
Chen, Lei
Liu, Siyuan
Wang, Chenfei
Xu, Yingzhi
Tedcastle, Alison
Gao, Fan
Mao, Qunying
Martin, Javier
Liang, Zhenglun
author_sort Liu, Pei
collection PubMed
description Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here, we tested the cross-neutralizing activities induced by EV71 genotype/sub-genotype A, B0-B4, C1, C2, C4, and C5 viruses using rats. Differences were noted in the cross-neutralization of the 10 sub-genotypes tested but there were generally good levels of cross-neutralization except against genotype A virus, against which neutralization antibody titres (NTAb) where the lowest with NTAbs being the highest against sub-genotype B4. Moreover, NTAb responses induced by C4, B4, C1, and C2 viruses were homogenous, with values of maximum/minimum NTAb ratios (MAX/MIN) against all B and C viruses ranging between 4.0 and 6.0, whereas MAX/MIN values against B3 and A viruses were highly variable, 48.0 and 256.0, respectively. We then dissected the cross-neutralizing ability of sera from infants and children and rats immunized with C4 EV71 vaccines. Cross-neutralizing titers against the 10 sub-genotypes were good in both vaccinated infants and children and rats with the MAX/MIN ranging from 1.8–3.4 and 5.1–7.1, respectively, which were similar to those found in naturally infected patients (2.8). Therefore, we conclude that C4 EV71 vaccines can provide global protection to infants and children against HFMD caused by different sub-genotypes.
format Online
Article
Text
id pubmed-8143144
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81431442021-05-25 Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy Liu, Pei Yuan, Yadi Cui, Bopei Huo, Yaqian Bian, Lianlian Chen, Lei Liu, Siyuan Wang, Chenfei Xu, Yingzhi Tedcastle, Alison Gao, Fan Mao, Qunying Martin, Javier Liang, Zhenglun Viruses Article Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here, we tested the cross-neutralizing activities induced by EV71 genotype/sub-genotype A, B0-B4, C1, C2, C4, and C5 viruses using rats. Differences were noted in the cross-neutralization of the 10 sub-genotypes tested but there were generally good levels of cross-neutralization except against genotype A virus, against which neutralization antibody titres (NTAb) where the lowest with NTAbs being the highest against sub-genotype B4. Moreover, NTAb responses induced by C4, B4, C1, and C2 viruses were homogenous, with values of maximum/minimum NTAb ratios (MAX/MIN) against all B and C viruses ranging between 4.0 and 6.0, whereas MAX/MIN values against B3 and A viruses were highly variable, 48.0 and 256.0, respectively. We then dissected the cross-neutralizing ability of sera from infants and children and rats immunized with C4 EV71 vaccines. Cross-neutralizing titers against the 10 sub-genotypes were good in both vaccinated infants and children and rats with the MAX/MIN ranging from 1.8–3.4 and 5.1–7.1, respectively, which were similar to those found in naturally infected patients (2.8). Therefore, we conclude that C4 EV71 vaccines can provide global protection to infants and children against HFMD caused by different sub-genotypes. MDPI 2021-04-21 /pmc/articles/PMC8143144/ /pubmed/33919184 http://dx.doi.org/10.3390/v13050720 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Pei
Yuan, Yadi
Cui, Bopei
Huo, Yaqian
Bian, Lianlian
Chen, Lei
Liu, Siyuan
Wang, Chenfei
Xu, Yingzhi
Tedcastle, Alison
Gao, Fan
Mao, Qunying
Martin, Javier
Liang, Zhenglun
Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title_full Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title_fullStr Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title_full_unstemmed Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title_short Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
title_sort cross-antigenicity between ev71 sub-genotypes: implications for vaccine efficacy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143144/
https://www.ncbi.nlm.nih.gov/pubmed/33919184
http://dx.doi.org/10.3390/v13050720
work_keys_str_mv AT liupei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT yuanyadi crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT cuibopei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT huoyaqian crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT bianlianlian crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT chenlei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT liusiyuan crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT wangchenfei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT xuyingzhi crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT tedcastlealison crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT gaofan crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT maoqunying crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT martinjavier crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy
AT liangzhenglun crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy